Skip to main content

Table 3 Percentage of free-events patients over months when associated the expression of proteins related to glycolytic metabolism with survivals (univariate analysis)

From: CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

Characteristics

Categories

Cases (n)

DFS

DSS

OS

24 mo

60 mo

120 mo

p

24 mo

60 mo

120 mo

p

24 mo

60 mo

120 mo

p

MCT1

Negative

174

86.8

68.7

19.5

0.136

91.4

68.6

55.4

0.361

91.4

66.6

51.8

0.507

Positive

12

91.7

83.3

41.7

 

91.7

83.3

41.7

 

91.7

83.3

31.3

 

MCT4

Negative

163

85.7

66.6

22.0

0.259

90.7

68.7

49.2

0.982

89.6

66.7

45.7

0.364

Positive

17

88.2

57.8

28.9

 

88.2

63.5

63.5

 

88.2

52.9

45.4

 

CD147

Negative

181

86.7

66.4

20.5

0.072

90.6

68.2

48.9

0.374

90.6

67.3

45.8

0.085

Positive

4

75.0

25.0

25.0

 

75.0

50.0

50.0

 

75.0

25.0

25.0

 

GLUT1

Negative

153

89.4

66.9

20.5

0.683

92.1

69.2

47.2

0.567

90.8

66.6

43.4

0.584

Positive

36

83.3

66.7

37.7

 

91.7

69.2

65.2

 

91.7

66.7

58.8

 

CAIX

Negative

163

84.6

66.1

18.3

0.005

89.6

66.0

45.5

0.012

89.6

64.9

42.9

0.143

Positive

13

100.0

100.0

100.0

 

100.0

100.0

100.0

 

92.3

84.6

75.2

 
  1. DFS Disease-free survival, DSS Disease-specific survival, OS Overall survival, mo Months. Significant values are shown in bold